Mobile website
Archive > Volume 24 Issue 6 > 2017,24(6):665-669. DOI:10.3872/j.issn.1007-385X.2017.06.016 Prev Next
Clinical Research
Clinical evaluation of dendritic cellcytokine induced killer cells immunotherapy combined with conventional treatment in patients with renal carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the clinical efficacy of adjuvant dendrtic cell (DC)cytokineinduced killer (CIK) cells immunotherapy and the effect of DCCIK cells treatment courses on the prognosis of patients with renal clear cell carcinoma. Methods: One hundred patients with renal clear cell carcinoma treated in Fujian Provincial Tumor Hospital from Jan, 2004 to Jun, 2011 were included in this retrospective study; 63 patients received DCCIK cells immunotherapy combined with conventional therapy were regarded as DCCIK cells treatment group, while the other 37 patients didn't receive DCCIK cells therapy were regarded as control group. The 5year DFS and OS of the two groups were compared. The treatment group was further subgrouped according to the course > 3 and course ≤3, and the 5year DFS and OS were further compared between the two subgroups. Results: Survival analysis showed the 5years overall survival (OS) rate was significantly higher in the DCCIK group compared with the control group (81.05% vs 60.29%, P<0.05), however, there was no significant difference in 5year DFS rate between two groups. Further subgroup analysis stratified according to the course of DCCIK cells treatment showed that the 5years OS was significantly improved in the group with course greater than 3 (P<0.05), although there was no significant difference in 5years DFS rate between two subgroups (P>0.05). Conclusion: Our results demonstrated that renal carcinoma patients could benefit from autologous DCCIK cells immunotherapy in combination with conventional therapies in terms of increasing overall survival. And the course of DCCIK cells treatment is closely related with the prognosis of patients with renal cell carcinoma.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Fujian Province (No. 2016J01514), and the Science and Technology Program of Fujian Province (No. 2017Y0022)
Clc Number:
